Brought to you by 
Series D brings $34.5mm to Avid Radiopharmaceuticals
28 May 2009
Executive Summary
Molecular imaging company Avid Radiopharmaceuticals brought in $34.5mm via its Series D round led by Alta Partners, which adds a board member. Joining first-timer Alta were returning shareholders AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group, and BioAdvance. Funds will be used to finish developing and launch the company's amyloid imaging agent 18FAV45 for Alzheimer's disease, and for ongoing Phase II trials of 18FAV133 for Parkinson's.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D brings $34.5mm to Avid Radiopharmaceuticals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice